Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers | Zendy

Nehal N. Mehta | Zendy; Daniel B. Shin | Zendy; Aditya A. Joshi | Zendy; Amit K. Dey | Zendy; April Armstrong | Zendy; Kristina Callis Duffin | Zendy; Zelma C. Chiesa Fuxench | Zendy; Charlotte Harrington | Zendy; Rebecca A. Hubbard | Zendy; Robert E. Kalb | Zendy; Alan Menter | Zendy; Daniel J. Rader | Zendy; Muredach P. Reilly | Zendy; Eric L. Simpson | Zendy; Junko Takeshita | Zendy; Drew A. Torigian | Zendy; Thomas Werner | Zendy; Andrea B. Troxel | Zendy; Stephen K. Tyring | Zendy; Suzette Báez Vanderbeek | Zendy; Abby S. Van Voorhees | Zendy; Martin P. Playford | Zendy; Mark A. Ahlman | Zendy; Abass Alavi | Zendy; Joel M. Gelfand | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers

Author(s) -

Nehal N. Mehta,

Daniel B. Shin,

Aditya A. Joshi,

Amit K. Dey,

April Armstrong,

Kristina Callis Duffin,

Zelma C. Chiesa Fuxench,

Charlotte Harrington,

Rebecca A. Hubbard,

Robert E. Kalb,

Alan Menter,

Daniel J. Rader,

Muredach P. Reilly,

Eric L. Simpson,

Junko Takeshita,

Drew A. Torigian,

Thomas Werner,

Andrea B. Troxel,

Stephen K. Tyring,

Suzette Báez Vanderbeek,

Abby S. Van Voorhees,

Martin P. Playford,

Mark A. Ahlman,

Abass Alavi,

Joel M. Gelfand

Publication year - 2018

Publication title -

circulation cardiovascular imaging

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.584

H-Index - 99

eISSN - 1942-0080

pISSN - 1941-9651

DOI - 10.1161/circimaging.117.007394

Subject(s) - adalimumab , medicine , gastroenterology , insulin resistance , inflammation , psoriasis , metabolic syndrome , placebo , dyslipidemia , confidence interval , immunology , pathology , tumor necrosis factor alpha , insulin , disease , obesity , alternative medicine

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research